These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18318942)

  • 41. Intravenous immunoglobulin treatment in a HIV-1 positive patient with Guillain-Barré syndrome.
    Rosca EC; Rosca O; Simu M
    Int Immunopharmacol; 2015 Dec; 29(2):964-965. PubMed ID: 26428850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of miltefosine in the treatment of visceral leishmaniasis in children at a tertiary care hospital of Karachi.
    Humayun KN; Saleem T; Khalid U; Jehan F; Soofi S
    J Pak Med Assoc; 2010 Jun; 60(6):489-91. PubMed ID: 20527651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Availability of miltefosine for the treatment of kala-azar in India.
    Sundar S; Murray HW
    Bull World Health Organ; 2005 May; 83(5):394-5. PubMed ID: 15976883
    [No Abstract]   [Full Text] [Related]  

  • 46. Reversible focal encephalic abnormalities in a patient with Guillain-Barré syndrome.
    Cruto CA; Pinto NC; Pato MV
    Arq Neuropsiquiatr; 2012 Jun; 70(6):471-2. PubMed ID: 22699548
    [No Abstract]   [Full Text] [Related]  

  • 47. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
    Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
    Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
    Monge-Maillo B; López-Vélez R
    Clin Infect Dis; 2015 May; 60(9):1398-404. PubMed ID: 25601455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Temporarily controlled HIV-1 replication after intravenous immunoglobulin treatment of Guillain-Barré syndrome.
    Gisslén M; Fredman P; Fuchs D; Lekman A; Rosengren L
    Scand J Infect Dis; 2005; 37(11-12):877-81. PubMed ID: 16308224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
    Antinori S; Longhi E; Bestetti G; Piolini R; Acquaviva V; Foschi A; Trovati S; Parravicini C; Corbellino M; Meroni L
    Br J Dermatol; 2007 Nov; 157(5):1032-6. PubMed ID: 17854365
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Santos J; Rivero A; Márquez M
    An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
    [No Abstract]   [Full Text] [Related]  

  • 52. Guillain Barre' syndrome--in an HIV seropositive subject.
    Hassan KM; Mathew I
    J Assoc Physicians India; 2000 Dec; 48(12):1214. PubMed ID: 11280235
    [No Abstract]   [Full Text] [Related]  

  • 53. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
    Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Visceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease.
    Martín A; Marques L; Soler-Palacín P; Caragol I; Hernandez M; Figueras C; Español T
    Pediatr Infect Dis J; 2009 Aug; 28(8):753-4. PubMed ID: 19633526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
    Shakya N; Sane SA; Vishwakarma P; Gupta S
    Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Miltefosine: a new remedy for leishmaniasis].
    Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
    Pandey BD; Pandey K; Kaneko O; Yanagi T; Hirayama K
    Am J Trop Med Hyg; 2009 Apr; 80(4):580-2. PubMed ID: 19346379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).
    Pourahmad M; Hooshmand F; Rahiminejad M
    Int J Dermatol; 2009 Jan; 48(1):59-61. PubMed ID: 19126052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atypical American visceral leishmaniasis caused by disseminated Leishmania amazonensis infection presenting with hepatitis and adenopathy.
    Aleixo JA; Nascimento ET; Monteiro GR; Fernandes MZ; Ramos AM; Wilson ME; Pearson RD; Jeronimo SM
    Trans R Soc Trop Med Hyg; 2006 Jan; 100(1):79-82. PubMed ID: 16198385
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
    Schraner C; Hasse B; Hasse U; Baumann D; Faeh A; Burg G; Grimm F; Mathis A; Weber R; Günthard HF
    Clin Infect Dis; 2005 Jun; 40(12):e120-4. PubMed ID: 15909255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.